Somewhat Positive Press Coverage Somewhat Unlikely to Impact Adamis Pharmaceuticals (ADMP) Stock Price
News stories about Adamis Pharmaceuticals (NASDAQ:ADMP) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Adamis Pharmaceuticals earned a news impact score of 0.08 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 45.9295983533559 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- Adamis Pharmaceuticals (ADMP) Price Target Cut to $0.00 (americanbankingnews.com)
- Notable Indicators to Study Before Making Any Investment Decision – Adamis Pharmaceuticals Corporation, (NASDAQ … – Stock Watch (stocksnewstimes.com)
- Technical Recap on Adamis Pharmaceuticals Corporation (ADMP) – Wall Street Morning (wallstreetmorning.com)
- Adamis Pharmaceuticals Corporation (ADMP) -Noteworthy Healthcare stock – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) – Hot Stock in Focus – Nasdaq Journal (nasdaqjournal.com)
A number of equities analysts recently issued reports on the company. B. Riley set a $10.00 price objective on Adamis Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, November 15th. Zacks Investment Research upgraded Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Maxim Group set a $14.00 price objective on Adamis Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 5th. ValuEngine cut Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 30th. Finally, Raymond James Financial set a $7.00 price objective on Adamis Pharmaceuticals and gave the company a “buy” rating in a report on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $7.33.
TRADEMARK VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Adamis Pharmaceuticals (ADMP) Stock Price” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2018/03/14/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-adamis-pharmaceuticals-admp-stock-price.html.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.